AB Science
A8D
Company Profile
Business description
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Contact
3, Avenue George V
Paris75008
FRAT: +33 147200014
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
45
Stocks News & Analysis
stocks
16 ASX stocks to buy and hold forever, revisited
This time last year, I highlighted 16 ASX stocks that investors could own indefinitely. One year on, I look at whether there should be any changes to the list of stocks as well as which companies are worth buying now.
stocks
This ASX200 reject could be a contrarian buying opportunity
Johns Lyng’s interim results and index deletion have sent investors running for the exits. Our analyst Esther Holloway thinks the sell-off is overdone.
stocks
A 15 step checklist from Buffett's forgotten inspiration
Phil Fisher achieved remarkable stock market returns by holding high quality growth companies for long periods of time. Here's how he found them.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,982.40 | 121.00 | -1.49% |
| CAC 40 | 7,941.91 | 105.69 | -1.31% |
| DAX 40 | 22,328.77 | 292.18 | -1.29% |
| Dow JONES (US) | 41,433.48 | 478.23 | -1.14% |
| FTSE 100 | 8,495.99 | 104.23 | -1.21% |
| HKSE | 23,721.52 | 60.62 | -0.25% |
| NASDAQ | 17,436.10 | 32.22 | -0.18% |
| Nikkei 225 | 36,898.83 | 105.72 | 0.29% |
| NZX 50 Index | 12,273.83 | 137.14 | -1.10% |
| S&P 500 | 5,572.07 | 42.49 | -0.76% |
| S&P/ASX 200 | 7,763.40 | 126.70 | -1.61% |
| SSE Composite Index | 3,374.08 | 5.75 | -0.17% |